Fredun Pharmaceuticals Ltd - 539730 - Audited Financial Results For The Quarter And Year Ended 31St March, 2020 Along With Auditors Report
With reference to the BSE mail dated 10.08.2020 regarding Discrepancies in Financial Results, we have rectified the Audited Financial Results and we are sending the revised Audited Financial Results for the quarter and year ended 31st March, 2020 along with the Auditors Report. Fredun Pharmaceuticals Ltd - 539730 - Live Webinar
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Corporate Capital Ventures Private Limited is organising a webinar under its 'Sustain & Emerge Post COVID- 19' series (an initiative taken for disseminating information for the benefit of investors). In the Episode 5 of this series Mr. Fredun Medhora, Managing Director & CFO of Fredun Pharmaceuticals Limited will be participating and representing the Company on Friday, August 07, 2020 at 5 pm. The link of the webinar is hereby given for your reference and will also be available on the website of the Company www.fredungroup.com. https://us02web.zoom.us/webinar/register/WN_IVDE5sb1RqeG_Xi0vdQKWA Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and 'Code of Conduct for prevention of Insider Trading' of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), the Trading Window for dealing in securities of the Company will remain closed from 1st July, 2020 till 48 hours after declaration of the Unaudited Financial Results of the Company for the first quarter ended 30th June, 2020 for the designated persons. Accordingly, all the Designated Persons of the Company have been advised not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Year ended March 31st 2020; as approved by the Board in its Meeting held on Wednesday, July 29, 2020; published in Business Standard & Mumbai Lakshadeep newspaper(s) on July 31, 2020. Fredun Pharmaceuticals Ltd - 539730 - Disclosure Of Material Impact Of COVID-19 Pandemic On Listed Entities Under LODR (Listing Obligations And Disclosure Requirements) Regulations,2015
With reference to the above captioned subject, please find the attached herewith the detailed update on impact of COVID-19 on the operations of the Company pursuant to SEBI's advisory Circular dated May 20, 2020. Kindly take the same on your record. Fredun Pharmaceuticals Ltd - 539730 - Outcome Of Board Meeting Held On 29Th July, 2020
1. The Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2020; Statement of Assets and Liabilities and Cash Flow Statement, Profit & Loss A/c, Schedules and Notes along with the Auditors Report issued by M/s. Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Recommended Final Dividend @ 6.6% i.e., Rs. 0.66/- per Equity Share having face value of Rs. 10/- each for the Financial Year 2019-20; subject to the approval of the shareholders at the ensuing 33rd Annual General Meeting of the Company; Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend
Board of Directors has approved a dividend of Rs. 0.66per equity share for the financial year 31st March, 2020 subject to approval of shareholders at ensuing Annual General Meeting Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47 of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Notice of the ensuing Board Meeting of the Company scheduled to be held on Wednesday, July 29, 2020; published in Business Standard & Mumbai Lakshadeep newspapers on July 24, 2020. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Fredun Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed. Fredun Pharmaceuticals Ltd - 539730 - Clarification sought from Fredun Pharmaceuticals Ltd
The Exchange has sought clarification from Fredun Pharmaceuticals Ltd on July 24, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.